ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: According to the National Comprehensive Cancer Network, all TKIs are highly effective in the newly diagnosed chronic phase of CML,[9] and the vast majority of CML patients can achieve complete molecular remission with no BCR-ABL1 rearrangement using reverse transcription quantitative polymerase chain reaction (RT–qPCR) after TKI therapy.